$ADVM
Adverum Biotechnologies, Inc.

2022 Q3 Form 10-Q Financial Statement

#000162828022022469 Filed on August 11, 2022

View on sec.gov

Income Statement

Concept 2022 Q3 2022 Q2 2022 Q1
Revenue $0.00 $0.00 $0.00
YoY Change -100.0%
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $17.19M $13.76M $15.17M
YoY Change 28.72% -37.25% -4.36%
% of Gross Profit
Research & Development $23.85M $30.27M $22.96M
YoY Change -0.91% 33.87% 14.93%
% of Gross Profit
Depreciation & Amortization $1.788M $1.603M $1.425M
YoY Change 85.86% 34.59% 21.79%
% of Gross Profit
Operating Expenses $41.04M $44.03M $38.13M
YoY Change 6.53% -1.15% 5.51%
Operating Profit -$41.04M -$44.03M -$38.13M
YoY Change 6.53% -1.15% 33.13%
Interest Expense
YoY Change
% of Operating Profit
Other Income/Expense, Net $923.0K $283.0K $244.0K
YoY Change 476.88% 38.05% 17.87%
Pretax Income -$40.11M -$43.74M -$37.89M
YoY Change 4.57% -1.33% 33.24%
Income Tax $17.00K $19.00K $19.00K
% Of Pretax Income
Net Earnings -$40.13M -$43.76M -$37.91M
YoY Change 4.61% -1.29% 33.31%
Net Earnings / Revenue
Basic Earnings Per Share -$0.40 -$0.44 -$0.38
Diluted Earnings Per Share -$0.40 -$0.44 -$0.38
COMMON SHARES
Basic Shares Outstanding 99.33M shares 99.00M shares 98.60M shares
Diluted Shares Outstanding 99.48M shares 99.00M shares 98.60M shares

Balance Sheet

Concept 2022 Q3 2022 Q2 2022 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments $203.3M $235.8M $271.1M
YoY Change -38.91% -35.18% -32.91%
Cash & Equivalents $84.43M $91.87M $89.65M
Short-Term Investments $118.8M $144.0M $181.4M
Other Short-Term Assets $9.979M $10.19M $9.062M
YoY Change 28.53% 63.48% 56.24%
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets $213.2M $246.0M $280.1M
YoY Change -38.69% -36.31% -31.65%
LONG-TERM ASSETS
Property, Plant & Equipment $36.58M $38.23M $37.22M
YoY Change -1.56% 21.03% 31.16%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $155.0K $277.0K $220.0K
YoY Change 12.32% 116.41% -55.38%
Total Long-Term Assets $119.1M $128.9M $127.3M
YoY Change -16.56% -7.83% 146.2%
TOTAL ASSETS
Total Short-Term Assets $213.2M $246.0M $280.1M
Total Long-Term Assets $119.1M $128.9M $127.3M
Total Assets $332.4M $375.0M $407.4M
YoY Change -32.25% -28.74% -11.73%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $846.0K $4.698M $3.245M
YoY Change -66.39% 107.97% 57.83%
Accrued Expenses $27.47M $25.74M $18.56M
YoY Change 27.43% 40.9% 3.69%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $28.62M $30.62M $23.24M
YoY Change 13.01% 49.15% 16.63%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00 $0.00
YoY Change
Other Long-Term Liabilities $940.0K $1.020M $1.027M
YoY Change -15.62% -8.44% -7.81%
Total Long-Term Liabilities $940.0K $1.020M $1.027M
YoY Change -15.62% -8.44% -7.81%
TOTAL LIABILITIES
Total Short-Term Liabilities $28.62M $30.62M $23.24M
Total Long-Term Liabilities $940.0K $1.020M $1.027M
Total Liabilities $124.0M $130.8M $124.4M
YoY Change -14.22% -11.0% 166.29%
SHAREHOLDERS EQUITY
Retained Earnings -$769.9M -$729.7M -$686.0M
YoY Change 25.45% 26.84% 29.19%
Common Stock $980.2M $975.7M $970.4M
YoY Change 2.08% 2.18% 2.56%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $208.3M $244.1M $283.0M
YoY Change
Total Liabilities & Shareholders Equity $332.4M $375.0M $407.4M
YoY Change -32.25% -28.74% -11.73%

Cashflow Statement

Concept 2022 Q3 2022 Q2 2022 Q1
OPERATING ACTIVITIES
Net Income -$40.13M -$43.76M -$37.91M
YoY Change 4.61% -1.29% 33.31%
Depreciation, Depletion And Amortization $1.788M $1.603M $1.425M
YoY Change 85.86% 34.59% 21.79%
Cash From Operating Activities -$31.81M -$28.88M -$28.93M
YoY Change 23.31% -14.84% 29.7%
INVESTING ACTIVITIES
Capital Expenditures -$824.0K -$6.433M $4.374M
YoY Change -85.59% 76.15% 211.54%
Acquisitions
YoY Change
Other Investing Activities $25.19M $37.17M $88.76M
YoY Change 55.61% -10.28% 1012.24%
Cash From Investing Activities $24.37M $30.74M $84.38M
YoY Change 132.74% -18.64% 1182.61%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net $0.00
YoY Change -100.0%
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 0.000 362.0K $3.000K
YoY Change -29.3% -99.8%
NET CHANGE
Cash From Operating Activities -31.81M -28.88M -$28.93M
Cash From Investing Activities 24.37M 30.74M $84.38M
Cash From Financing Activities 0.000 362.0K $3.000K
Net Change In Cash -7.440M 2.218M $55.46M
YoY Change -51.46% -49.34% -489.97%
FREE CASH FLOW
Cash From Operating Activities -$31.81M -$28.88M -$28.93M
Capital Expenditures -$824.0K -$6.433M $4.374M
Free Cash Flow -$30.98M -$22.45M -$33.30M
YoY Change 54.33% -25.82% 40.47%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
dei Amendment Flag
AmendmentFlag
false
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2022
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q2
dei Entity Central Index Key
EntityCentralIndexKey
0001501756
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
dei Document Type
DocumentType
10-Q
dei Document Quarterly Report
DocumentQuarterlyReport
true
dei Document Period End Date
DocumentPeriodEndDate
2022-06-30
dei Document Transition Report
DocumentTransitionReport
false
dei Entity File Number
EntityFileNumber
001-36579
dei Entity Registrant Name
EntityRegistrantName
Adverum Biotechnologies, Inc.
dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
dei Entity Tax Identification Number
EntityTaxIdentificationNumber
20-5258327
dei Entity Address Address Line1
EntityAddressAddressLine1
100 Cardinal Way
dei Entity Address City Or Town
EntityAddressCityOrTown
Redwood City
dei Entity Address State Or Province
EntityAddressStateOrProvince
CA
dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
94063
dei City Area Code
CityAreaCode
650
dei Local Phone Number
LocalPhoneNumber
656-9323
dei Security12b Title
Security12bTitle
Common Stock, $0.0001 par value
dei Trading Symbol
TradingSymbol
ADVM
dei Security Exchange Name
SecurityExchangeName
NASDAQ
dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
dei Entity Small Business
EntitySmallBusiness
true
dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
false
dei Entity Shell Company
EntityShellCompany
false
CY2022Q3 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
99333578 shares
CY2022Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
91870000 usd
CY2021Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
34195000 usd
CY2022Q2 us-gaap Short Term Investments
ShortTermInvestments
143971000 usd
CY2021Q4 us-gaap Short Term Investments
ShortTermInvestments
270993000 usd
CY2022Q2 us-gaap Incentive To Lessee
IncentiveToLessee
0 usd
CY2021Q4 us-gaap Incentive To Lessee
IncentiveToLessee
5709000 usd
CY2022Q2 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
10190000 usd
CY2021Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
6248000 usd
CY2022Q2 us-gaap Assets Current
AssetsCurrent
246031000 usd
CY2021Q4 us-gaap Assets Current
AssetsCurrent
317145000 usd
CY2022Q2 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
83766000 usd
CY2021Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
86000000 usd
CY2022Q2 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
38233000 usd
CY2021Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
33060000 usd
CY2022Q2 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
2503000 usd
CY2021Q4 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
2503000 usd
CY2022Q2 us-gaap Deferred Rent Receivables Net
DeferredRentReceivablesNet
4145000 usd
CY2021Q4 us-gaap Deferred Rent Receivables Net
DeferredRentReceivablesNet
769000 usd
CY2022Q2 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
277000 usd
CY2021Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
250000 usd
CY2022Q2 us-gaap Assets
Assets
374955000 usd
CY2021Q4 us-gaap Assets
Assets
439727000 usd
CY2022Q2 us-gaap Accounts Payable Current
AccountsPayableCurrent
4698000 usd
CY2021Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
1387000 usd
CY2022Q2 advm Accrued Expenses And Other Current Liabilities
AccruedExpensesAndOtherCurrentLiabilities
19630000 usd
CY2021Q4 advm Accrued Expenses And Other Current Liabilities
AccruedExpensesAndOtherCurrentLiabilities
18047000 usd
CY2022Q2 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
6292000 usd
CY2021Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
1886000 usd
CY2022Q2 us-gaap Liabilities Current
LiabilitiesCurrent
30620000 usd
CY2021Q4 us-gaap Liabilities Current
LiabilitiesCurrent
21320000 usd
CY2022Q2 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
99193000 usd
CY2021Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
101108000 usd
CY2022Q2 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
1020000 usd
CY2021Q4 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
1114000 usd
CY2022Q2 us-gaap Liabilities
Liabilities
130833000 usd
CY2021Q4 us-gaap Liabilities
Liabilities
123542000 usd
CY2022Q2 us-gaap Preferred Stock Value
PreferredStockValue
0 usd
CY2021Q4 us-gaap Preferred Stock Value
PreferredStockValue
0 usd
CY2022Q2 us-gaap Common Stock Value
CommonStockValue
10000 usd
CY2021Q4 us-gaap Common Stock Value
CommonStockValue
10000 usd
CY2022Q2 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
975653000 usd
CY2021Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
964965000 usd
CY2022Q2 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-1796000 usd
CY2021Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-714000 usd
CY2022Q2 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-729745000 usd
CY2021Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-648076000 usd
CY2022Q2 us-gaap Stockholders Equity
StockholdersEquity
244122000 usd
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
316185000 usd
CY2022Q2 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
374955000 usd
CY2021Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
439727000 usd
CY2022Q2 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
0 usd
CY2021Q2 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
0 usd
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
0 usd
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
7500000 usd
CY2022Q2 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
30265000 usd
CY2021Q2 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
22608000 usd
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
53229000 usd
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
42588000 usd
CY2022Q2 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
13760000 usd
CY2021Q2 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
21930000 usd
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
28929000 usd
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
38093000 usd
CY2022Q2 us-gaap Operating Expenses
OperatingExpenses
44025000 usd
CY2021Q2 us-gaap Operating Expenses
OperatingExpenses
44538000 usd
us-gaap Operating Expenses
OperatingExpenses
82158000 usd
us-gaap Operating Expenses
OperatingExpenses
80681000 usd
CY2022Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-44025000 usd
CY2021Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-44538000 usd
us-gaap Operating Income Loss
OperatingIncomeLoss
-82158000 usd
us-gaap Operating Income Loss
OperatingIncomeLoss
-73181000 usd
CY2022Q2 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
283000 usd
CY2021Q2 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
205000 usd
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
527000 usd
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
412000 usd
CY2022Q2 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-43742000 usd
CY2021Q2 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-44333000 usd
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-81631000 usd
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-72769000 usd
CY2022Q2 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
19000 usd
CY2021Q2 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0 usd
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
38000 usd
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0 usd
CY2022Q2 us-gaap Net Income Loss
NetIncomeLoss
-43761000 usd
CY2021Q2 us-gaap Net Income Loss
NetIncomeLoss
-44333000 usd
us-gaap Net Income Loss
NetIncomeLoss
-81669000 usd
us-gaap Net Income Loss
NetIncomeLoss
-72769000 usd
CY2022Q2 us-gaap Marketable Securities Unrealized Gain Loss
MarketableSecuritiesUnrealizedGainLoss
-339000 usd
CY2021Q2 us-gaap Marketable Securities Unrealized Gain Loss
MarketableSecuritiesUnrealizedGainLoss
-62000 usd
us-gaap Marketable Securities Unrealized Gain Loss
MarketableSecuritiesUnrealizedGainLoss
-1062000 usd
us-gaap Marketable Securities Unrealized Gain Loss
MarketableSecuritiesUnrealizedGainLoss
-84000 usd
CY2022Q2 us-gaap Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent
-34000 usd
CY2021Q2 us-gaap Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent
-39000 usd
us-gaap Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent
-20000 usd
us-gaap Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent
-72000 usd
CY2022Q2 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-44134000 usd
CY2021Q2 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-44434000 usd
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-82751000 usd
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-72925000 usd
CY2022Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.44
CY2022Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.44
CY2021Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.45
CY2021Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.45
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.83
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.83
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.74
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.74
CY2022Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
99000000 shares
CY2022Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
99000000 shares
CY2021Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
98018000 shares
CY2021Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
98018000 shares
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
98799000 shares
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
98799000 shares
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
97885000 shares
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
97885000 shares
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
316185000 usd
CY2022Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
5381000 usd
CY2022Q1 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
3000 usd
CY2022Q1 us-gaap Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent
14000 usd
CY2022Q1 us-gaap Marketable Securities Unrealized Gain Loss
MarketableSecuritiesUnrealizedGainLoss
-723000 usd
CY2022Q1 us-gaap Net Income Loss
NetIncomeLoss
-37908000 usd
CY2022Q1 us-gaap Stockholders Equity
StockholdersEquity
282952000 usd
CY2022Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
4942000 usd
CY2022Q2 us-gaap Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
362000 usd
CY2022Q2 us-gaap Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent
-34000 usd
CY2022Q2 us-gaap Marketable Securities Unrealized Gain Loss
MarketableSecuritiesUnrealizedGainLoss
-339000 usd
CY2022Q2 us-gaap Net Income Loss
NetIncomeLoss
-43761000 usd
CY2022Q2 us-gaap Stockholders Equity
StockholdersEquity
244122000 usd
CY2020Q4 us-gaap Stockholders Equity
StockholdersEquity
434347000 usd
CY2021Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
7224000 usd
CY2021Q1 us-gaap Payments Of Stock Issuance Costs
PaymentsOfStockIssuanceCosts
5000 usd
CY2021Q1 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
1689000 usd
CY2021Q1 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
51000 usd
CY2021Q1 us-gaap Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent
-33000 usd
CY2021Q1 us-gaap Marketable Securities Unrealized Gain Loss
MarketableSecuritiesUnrealizedGainLoss
-22000 usd
CY2021Q1 us-gaap Net Income Loss
NetIncomeLoss
-28436000 usd
CY2021Q1 us-gaap Stockholders Equity
StockholdersEquity
414820000 usd
CY2021Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
8234000 usd
CY2021Q2 us-gaap Adjustments To Additional Paid In Capital Stock Issued Issuance Costs
AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts
4000 usd
CY2021Q2 us-gaap Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
526000 usd
CY2021Q2 us-gaap Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent
-39000 usd
CY2021Q2 us-gaap Marketable Securities Unrealized Gain Loss
MarketableSecuritiesUnrealizedGainLoss
-62000 usd
CY2021Q2 us-gaap Net Income Loss
NetIncomeLoss
-44333000 usd
CY2021Q2 us-gaap Stockholders Equity
StockholdersEquity
379142000 usd
us-gaap Net Income Loss
NetIncomeLoss
-81669000 usd
us-gaap Net Income Loss
NetIncomeLoss
-72769000 usd
us-gaap Depreciation And Amortization
DepreciationAndAmortization
3028000 usd
us-gaap Depreciation And Amortization
DepreciationAndAmortization
2361000 usd
us-gaap Share Based Compensation
ShareBasedCompensation
10323000 usd
us-gaap Share Based Compensation
ShareBasedCompensation
15458000 usd
us-gaap Accretion Amortization Of Discounts And Premiums Investments
AccretionAmortizationOfDiscountsAndPremiumsInvestments
-258000 usd
us-gaap Accretion Amortization Of Discounts And Premiums Investments
AccretionAmortizationOfDiscountsAndPremiumsInvestments
-1398000 usd
us-gaap Gain Loss On Sale Of Property Plant Equipment
GainLossOnSaleOfPropertyPlantEquipment
-101000 usd
us-gaap Gain Loss On Sale Of Property Plant Equipment
GainLossOnSaleOfPropertyPlantEquipment
0 usd
us-gaap Asset Impairment Charges
AssetImpairmentCharges
2011000 usd
us-gaap Asset Impairment Charges
AssetImpairmentCharges
0 usd
us-gaap Other Noncash Income Expense
OtherNoncashIncomeExpense
76000 usd
us-gaap Other Noncash Income Expense
OtherNoncashIncomeExpense
81000 usd
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
4165000 usd
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
1653000 usd
us-gaap Increase Decrease In Other Operating Assets
IncreaseDecreaseInOtherOperatingAssets
3403000 usd
us-gaap Increase Decrease In Other Operating Assets
IncreaseDecreaseInOtherOperatingAssets
99000 usd
advm Increase Decrease Operating Lease Right Of Use Asset
IncreaseDecreaseOperatingLeaseRightOfUseAsset
-2234000 usd
advm Increase Decrease Operating Lease Right Of Use Asset
IncreaseDecreaseOperatingLeaseRightOfUseAsset
-1505000 usd
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
3216000 usd
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-394000 usd
us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
2172000 usd
us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
-583000 usd
us-gaap Increase Decrease In Other Noncurrent Liabilities
IncreaseDecreaseInOtherNoncurrentLiabilities
-38000 usd
us-gaap Increase Decrease In Other Noncurrent Liabilities
IncreaseDecreaseInOtherNoncurrentLiabilities
0 usd
advm Increase Decrease In Lease Liabilities And Lease Incentive Receivable
IncreaseDecreaseInLeaseLiabilitiesAndLeaseIncentiveReceivable
8200000 usd
advm Increase Decrease In Lease Liabilities And Lease Incentive Receivable
IncreaseDecreaseInLeaseLiabilitiesAndLeaseIncentiveReceivable
-1363000 usd
us-gaap Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans
ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans
526000 usd
us-gaap Repayments Of Debt
RepaymentsOfDebt
0 usd
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-57808000 usd
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-56220000 usd
us-gaap Payments To Acquire Available For Sale Securities Debt
PaymentsToAcquireAvailableForSaleSecuritiesDebt
57674000 usd
us-gaap Payments To Acquire Available For Sale Securities Debt
PaymentsToAcquireAvailableForSaleSecuritiesDebt
199959000 usd
us-gaap Proceeds From Maturities Prepayments And Calls Of Available For Sale Securities
ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities
183599000 usd
us-gaap Proceeds From Maturities Prepayments And Calls Of Available For Sale Securities
ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities
240377000 usd
us-gaap Proceeds From Sale And Maturity Of Marketable Securities
ProceedsFromSaleAndMaturityOfMarketableSecurities
0 usd
us-gaap Proceeds From Sale And Maturity Of Marketable Securities
ProceedsFromSaleAndMaturityOfMarketableSecurities
8990000 usd
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
10807000 usd
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
5052000 usd
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
115118000 usd
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
44356000 usd
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
0 usd
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
1685000 usd
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
3000 usd
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
51000 usd
us-gaap Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans
ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans
362000 usd
us-gaap Repayments Of Debt
RepaymentsOfDebt
240000 usd
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
365000 usd
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
2022000 usd
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
57675000 usd
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-9842000 usd
CY2021Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
36698000 usd
CY2020Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
63423000 usd
CY2022Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
94373000 usd
CY2021Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
53581000 usd
CY2022Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
91870000 usd
CY2021Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
47299000 usd
CY2022Q2 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
2503000 usd
CY2021Q2 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
6282000 usd
CY2022Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
94373000 usd
CY2021Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
53581000 usd
us-gaap Right Of Use Asset Obtained In Exchange For Finance Lease Liability
RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability
0 usd
us-gaap Right Of Use Asset Obtained In Exchange For Finance Lease Liability
RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability
84005000 usd
us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
908000 usd
us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
1562000 usd
CY2022Q2 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-729700000 usd
CY2022Q2 us-gaap Cash Cash Equivalents And Short Term Investments
CashCashEquivalentsAndShortTermInvestments
235800000 usd
us-gaap Use Of Estimates
UseOfEstimates
<div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Use of Estimates</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying condensed consolidated financial statements have been prepared in accordance with U.S. GAAP. The preparation of the condensed consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, disclosure of contingent liabilities and the reported amounts of expenses in the condensed consolidated financial statements and the accompanying notes. On an ongoing basis, management evaluates its estimates, including those related to clinical trial accruals, fair value of assets and liabilities, impairment of long-lived assets, income taxes, and stock-based compensation. Management bases its estimates on historical experience and on various other market-specific and relevant assumptions that management believes to be reasonable under the circumstances. Actual results could differ from those estimates.</span></div>
CY2022Q2 advm Cash And Cash Equivalent Amortized Cost
CashAndCashEquivalentAmortizedCost
77342000 usd
CY2022Q2 advm Cash And Cash Equivalent Gross Unrealized Gain
CashAndCashEquivalentGrossUnrealizedGain
0 usd
CY2022Q2 advm Cash And Cash Equivalent Gross Unrealized Loss
CashAndCashEquivalentGrossUnrealizedLoss
10000 usd
CY2022Q2 us-gaap Cash And Cash Equivalents Fair Value Disclosure
CashAndCashEquivalentsFairValueDisclosure
77332000 usd
CY2022Q2 us-gaap Available For Sale Debt Securities Amortized Cost Basis
AvailableForSaleDebtSecuritiesAmortizedCostBasis
145340000 usd
CY2022Q2 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
0 usd
CY2022Q2 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
1369000 usd
CY2022Q2 us-gaap Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
143971000 usd
CY2021Q4 advm Cash And Cash Equivalent Amortized Cost
CashAndCashEquivalentAmortizedCost
25808000 usd
CY2021Q4 advm Cash And Cash Equivalent Gross Unrealized Gain
CashAndCashEquivalentGrossUnrealizedGain
0 usd
CY2021Q4 advm Cash And Cash Equivalent Gross Unrealized Loss
CashAndCashEquivalentGrossUnrealizedLoss
1000 usd
CY2021Q4 us-gaap Cash And Cash Equivalents Fair Value Disclosure
CashAndCashEquivalentsFairValueDisclosure
25807000 usd
CY2021Q4 us-gaap Available For Sale Debt Securities Amortized Cost Basis
AvailableForSaleDebtSecuritiesAmortizedCostBasis
271309000 usd
CY2021Q4 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
1000 usd
CY2021Q4 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
317000 usd
CY2021Q4 us-gaap Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
270993000 usd
CY2022Q2 advm Other Than Temporary Impaired Investments Available For Sale Securities
OtherThanTemporaryImpairedInvestmentsAvailableForSaleSecurities
0 usd
CY2022Q2 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
53874000 usd
CY2021Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
46234000 usd
CY2022Q2 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
15641000 usd
CY2021Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
13174000 usd
CY2022Q2 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
38233000 usd
CY2021Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
33060000 usd
CY2022Q2 us-gaap Asset Impairment Charges
AssetImpairmentCharges
2000000 usd
CY2022Q2 us-gaap Accrued Employee Benefits Current
AccruedEmployeeBenefitsCurrent
8128000 usd
CY2021Q4 us-gaap Accrued Employee Benefits Current
AccruedEmployeeBenefitsCurrent
9209000 usd
CY2022Q2 advm Accrued Nonclinical Clinical And Development Process Costs
AccruedNonclinicalClinicalAndDevelopmentProcessCosts
8387000 usd
CY2021Q4 advm Accrued Nonclinical Clinical And Development Process Costs
AccruedNonclinicalClinicalAndDevelopmentProcessCosts
4953000 usd
CY2022Q2 us-gaap Taxes Payable Current
TaxesPayableCurrent
178000 usd
CY2021Q4 us-gaap Taxes Payable Current
TaxesPayableCurrent
1318000 usd
CY2022Q2 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
986000 usd
CY2021Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
550000 usd
CY2022Q2 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
1951000 usd
CY2021Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
2017000 usd
CY2022Q2 advm Accrued Expenses And Other Current Liabilities
AccruedExpensesAndOtherCurrentLiabilities
19630000 usd
CY2021Q4 advm Accrued Expenses And Other Current Liabilities
AccruedExpensesAndOtherCurrentLiabilities
18047000 usd
CY2021Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
13288000 shares
CY2021Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
9.34
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
6994000 shares
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
1.33
us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
15000 shares
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
0.19
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
3469000 shares
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
5.96
CY2022Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
16798000 shares
CY2022Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
6.71
CY2022Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
4739000 shares
CY2022Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
12.02
CY2022Q2 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
4942000 usd
CY2021Q2 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
8234000 usd
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
10323000 usd
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
15458000 usd
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
19488000 shares
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
15130000 shares

Files In Submission

Name View Source Status
advm-20220630_cal.xml Edgar Link unprocessable
0001628280-22-022469-index-headers.html Edgar Link pending
0001628280-22-022469-index.html Edgar Link pending
0001628280-22-022469.txt Edgar Link pending
0001628280-22-022469-xbrl.zip Edgar Link pending
advm-20220630.htm Edgar Link pending
advm-20220630.xsd Edgar Link pending
advm-20220630ex311.htm Edgar Link pending
advm-20220630ex312.htm Edgar Link pending
advm-20220630ex321.htm Edgar Link pending
advm-20220630ex322.htm Edgar Link pending
advmlogo.jpg Edgar Link pending
ex101ajrakowofferletter.htm Edgar Link pending
ex101bjrakowpromotionlette.htm Edgar Link pending
ex101cjrakowpromotionsvp.htm Edgar Link pending
ex102dsouzaseparationagree.htm Edgar Link pending
ex103consultingagreementnp.htm Edgar Link pending
ex1042014esppplanamended.htm Edgar Link pending
Financial_Report.xlsx Edgar Link pending
image.jpg Edgar Link pending
imageb.jpg Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
advm-20220630_def.xml Edgar Link unprocessable
FilingSummary.xml Edgar Link unprocessable
advm-20220630_pre.xml Edgar Link unprocessable
advm-20220630_lab.xml Edgar Link unprocessable
advm-20220630_htm.xml Edgar Link completed
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R4.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending